Condition: Hepatitis Delta Virus · Sponsor: Eiger BioPharmaceuticals
Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral suppression and alanine aminotransferase (ALT) normalization. For each LNF-containing regimen, a composite endpoint of EOT (48 weeks) virologic response and ALT normalization will be used. Virologic response will be defined as a 2 log10 IU/mL reduction from baseline.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| UCSF Fresno | Fresno, California, United States | — |
| Ruane Clinical Research Group Inc. | Los Angeles, California, United States | — |
| Asia Pacific Liver Center | Los Angeles, California, United States | — |
| Stanford University | Palo Alto, California, United States | — |
| University of California Davis Health System | Sacramento, California, United States | — |
| Kaiser Permanente Medical Center Sacramento | Sacramento, California, United States | — |
| Yale University Medical Center | New Haven, Connecticut, United States | — |
| University of Miami Schiff Center for Liver Disease | Miami, Florida, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
| University of Iowa Hospitals & Clinics | Iowa City, Iowa, United States | — |
| National Institutes of Health | Bethesda, Maryland, United States | — |
| Henry Ford Health System | Detroit, Michigan, United States | — |
+ 104 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03719313